Short Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Expands By 122.3%

Key Points

• Short interest in SOPHiA GENETICS increased by 122.3% in August, with a total of 40,900 shares sold short.
• Several institutional investors have increased their positions in the company, including Federated Hermes Inc. with a 89.0% increase in shares.
• The company reported an earnings per share (EPS) of $0.33 for the last quarter, exceeding analyst expectations of ($0.25).

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) was the recipient of a significant increase in short interest in the month of August. As of August 15th, there was short interest totaling 40,900 shares, anincreaseof122.3% from the July 31st total of 18,400 shares. Based on an average daily volume of 96,700 shares, the days-to-cover ratio is currently 0.4 days. Approximately0.1% of the shares of the company are short sold. Approximately0.1% of the shares of the company are short sold. Based on an average daily volume of 96,700 shares, the days-to-cover ratio is currently 0.4 days.

SOPHiA GENETICS Stock Performance

Shares of NASDAQ SOPH traded down $0.10 during mid-day trading on Tuesday, hitting $3.22. 26,498 shares of the company were exchanged, compared to its average volume of 73,059. The company has a quick ratio of 3.21, a current ratio of 3.39 and a debt-to-equity ratio of 0.62. The stock has a 50 day simple moving average of $3.38 and a 200-day simple moving average of $3.18. SOPHiA GENETICS has a 1-year low of $2.58 and a 1-year high of $4.92. The firm has a market cap of $217.68 million, a price-to-earnings ratio of -7.33 and a beta of 1.01.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $0.33 EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.58. SOPHiA GENETICS had a negative return on equity of 30.69% and a negative net margin of 40.99%.The company had revenue of $18.32 million during the quarter, compared to the consensus estimate of $17.49 million. SOPHiA GENETICS has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that SOPHiA GENETICS will post -0.96 EPS for the current fiscal year.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Akre Capital Management LLC lifted its holdings in SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company's stock valued at $11,529,000 after acquiring an additional 1,481,636 shares during the period. Federated Hermes Inc. lifted its holdings in SOPHiA GENETICS by 16.4% in the second quarter. Federated Hermes Inc. now owns 220,000 shares of the company's stock valued at $682,000 after acquiring an additional 31,000 shares during the period. Archon Capital Management LLC acquired a new stake in SOPHiA GENETICS in the second quarter valued at $997,000. Ensign Peak Advisors Inc acquired a new stake in SOPHiA GENETICS in the second quarter valued at $775,000. Finally, Rathbones Group PLC acquired a new stake in SOPHiA GENETICS in the second quarter valued at $504,000. Institutional investors and hedge funds own 31.59% of the company's stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.